Genetic Technologies Limited (GENE)

Genetic Technologies Balance Sheet

Financials in millions AUD. Fiscal year is July - June.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	7.85	11.73	20.9	14.21	2.13
Cash & Cash Equivalents	7.85	11.73	20.9	14.21	2.13
Cash Growth	-33.07%	-43.88%	47.05%	566.79%	-61.15%
Receivables	1.92	2.42	1.07	0.79	0.82
Inventory	0.33	0.4	0.08	0.09	0.03
Other Current Assets	0.4	0.17	0.18	0.1	0.21
Total Current Assets	10.5	14.72	22.24	15.19	3.2
Property, Plant & Equipment	0.6	0.95	0.64	0.44	0.07
Goodwill and Intangibles	3.64	5.13	0	0	0
Other Long-Term Assets	0.12	0	0.1	0	0
Total Long-Term Assets	4.36	6.08	0.74	0.44	0.07
Total Assets	14.86	20.8	22.97	15.63	3.27
Accounts Payable	1.62	2.12	0.76	0.72	1.01
Deferred Revenue	0.85	0	0	0	0
Current Debt	0.3	0.26	0.18	0.24	0
Other Current Liabilities	0.54	1.43	0.46	0.43	0.49
Total Current Liabilities	3.31	3.81	1.41	1.4	1.49
Long-Term Debt	0.23	0.39	0.02	0.24	0
Other Long-Term Liabilities	0.15	0.17	0.01	0	0
Total Long-Term Liabilities	0.38	0.56	0.03	0.24	0
Total Liabilities	3.69	4.37	1.44	1.64	1.49
Total Debt	0.53	0.65	0.2	0.48	0
Debt Growth	-18.34%	219.81%	-57.65%	-	-
Retained Earnings	-156.72	-150.21	-143.08	-136.05	-129.74
Shareholders' Equity	11.16	16.43	21.53	13.99	1.77
Net Cash / Debt	7.32	11.08	20.7	13.73	2.13
Net Cash / Debt Growth	-33.94%	-46.47%	50.73%	544.19%	-61.15%
Net Cash Per Share	0.07	0.12	0.24	0.33	0.08
Working Capital	7.19	10.91	20.83	13.8	1.7
Book Value Per Share	66.06	106.92	151.21	202.06	40.32

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).